Pushing Forward or Staying the Course? Product Hopping, Exclusionary Conduct, and the Recent Suboxone MTD Ruling

Matthew Kent spoke at this event hosted by the American Bar Association Section of Antitrust Law and State Enforcement Committee.

The panel discussed, in conversational format, the recent ruling on the motion to dismiss the multistate complaint in the Suboxone case. Panelists provided background on the motion to dismiss and then addressed how the ruling fits within the existing state of the law with regard to both pharmaceutical product hops and conduct in the case that is alleged to have led to delayed generic entry (including REMS and FDA citizen petition issues).

For more information, click here.